Grant: Discovery Grants Program - Individual
University of Western Ontario
$28,000.00
""Optimal Pricing, Purchasing, and Co-Development with Applications in Public and Private Sector Pharmaceutical Management""
EF 2014-15
Résumé
I will investigate a number of issues related to optimal purchasing contracts, optimal pricing, and optimal co-development opportunities, all of which are motivated by management problems in the pharmaceutical and biotechnology industries. These topics (pricing, purchasing and co-development) are closely related and tied together by the following trends: 1. The use of cost-effectiveness or net benefits analysis as a criteria for drugs to be listed on formularies; 2. The increasing use of ""risk sharing"" contracts between drug purchasers, such as government insurance plans, and drug manufacturers; 3. The development of very expensive drugs which are only effective for a portion of the population; and 4. The promise of genetic tests to help identify, and thus target, those who are most likely to benefit from new targeted therapies. These trends lead to a number of challenging management problems for managers of public sector drug plans, as well as manufacturers of drugs and genetic tests. In this research I will develop operations research models to help gain insight into these problems. Note that the focus of this research is not on the clinical or basic science issues underlying these trends but rather on the development of mathematical models to address the management issues, in both the public and private sector, that arise from these trends.
Programme
Discovery Grants Program - Individual
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
NSERC's Awards Data
Tel que publié
Application id
228649-2012
Name nom
Zaric, Gregory
Department département
Richard Ivey School of Business
Organization id
36
Institution établissement
University of Western Ontario
Province en
Ontario
Province fr
Ontario
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2014
Competition year année de concours
2012
Award amount
28000
Program id
RGPIN
Program name en
Discovery Grants Program - Individual
Program name fr
Programme de subventions à la découverte - individuelles
Group en
Discovery grants programs
Group fr
Programmes de subventions à la découverte
Committee code
1509
Committee name en
Civil, Industrial and Systems Engineering
Committee name fr
Génie civil, industriel et des systèmes
Area of application code
520
Area of application group en
Manufacturing processes and products
Area of application group fr
Procédés et produits industriels
Area of application en
Production and operations management
Area of application fr
Production et gestion des opérations
Research subject code
1601
Research subject group en
Industrial engineering
Research subject group fr
Génie industriel
Research subject en
Operations research and management science
Research subject fr
Recherche opérationnelle et science de la gestion
Partie
3
Nb partie
5
Application title
""Optimal Pricing, Purchasing, and Co-Development with Applications in Public and Private Sector Pharmaceutical Management""
Keyword
NSERC
Application summary
I will investigate a number of issues related to optimal purchasing contracts, optimal pricing, and optimal co-development opportunities, all of which are motivated by management problems in the pharmaceutical and biotechnology industries. These topics (pricing, purchasing and co-development) are closely related and tied together by the following trends: 1. The use of cost-effectiveness or net benefits analysis as a criteria for drugs to be listed on formularies; 2. The increasing use of ""risk sharing"" contracts between drug purchasers, such as government insurance plans, and drug manufacturers; 3. The development of very expensive drugs which are only effective for a portion of the population; and 4. The promise of genetic tests to help identify, and thus target, those who are most likely to benefit from new targeted therapies. These trends lead to a number of challenging management problems for managers of public sector drug plans, as well as manufacturers of drugs and genetic tests. In this research I will develop operations research models to help gain insight into these problems. Note that the focus of this research is not on the clinical or basic science issues underlying these trends but rather on the development of mathematical models to address the management issues, in both the public and private sector, that arise from these trends.